Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

7.87
+0.06000.77%
Post-market: 7.870.00000.00%16:53 EST
Volume:1.61M
Turnover:12.73M
Market Cap:524.14M
PE:-6.66
High:8.40
Open:7.67
Low:7.58
Close:7.81
52wk High:15.74
52wk Low:2.32
Shares:66.60M
Float Shares:39.39M
Volume Ratio:0.69
T/O Rate:4.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1819
EPS(LYR):-1.1819
ROE:-25.30%
ROA:-16.90%
PB:1.50
PE(LYR):-6.66

Loading ...

Fulcrum Therapeutics Announces 12-Week Results from Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Reuters
·
Feb 17

Fulcrum’s Pociredir Trial Completion Adds a New Catalyst to the Sickle Cell Investment Story

TIPRANKS
·
Feb 13

Fulcrum Therapeutics Grants 70,000 Stock Options to New Employee

Reuters
·
Feb 07

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 07

Director Robert J. Gould Reports Sale of Fulcrum Therapeutics Inc. Common Shares

Reuters
·
Feb 05

Truist Financial Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

TIPRANKS
·
Feb 02

Fulcrum and Kpmg Announce Collaboration to Transform Utility Field Operations and Strengthen Operational Resiliency

THOMSON REUTERS
·
Jan 27

De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data

TIPRANKS
·
Jan 26

Fulcrum Therapeutics (FULC) Receives a Sell from Bank of America Securities

TIPRANKS
·
Jan 16

Fulcrum Therapeutics Showcases Pociredir's Promise as Best-in-Class Oral Therapy for Sickle Cell Disease

Reuters
·
Jan 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fulcrum Therapeutics (FULC), Teladoc (TDOC) and MDxHealth (MDXH)

TIPRANKS
·
Jan 13

Fulcrum Therapeutics updates strategy on lead sickle cell therapy

TIPRANKS
·
Jan 12

Fulcrum Therapeutics Initiated at Overweight by JP Morgan

Dow Jones
·
Jan 12

JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target

MT Newswires Live
·
Jan 12

Fulcrum Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $20

THOMSON REUTERS
·
Jan 12

Fulcrum Therapeutics Grants Stock Options to New Employees

Reuters
·
Jan 10

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 10

Director Robert J. Gould Reports Sale of Fulcrum Therapeutics Inc. Common Shares

Reuters
·
Jan 07

Chief Legal Officer Curt Oltmans Reports Sale of Fulcrum Therapeutics Common Shares

Reuters
·
Dec 18, 2025

Fulcrum Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
Dec 12, 2025